Abbott Laboratories ABT
104.71 USD -2.74 (-2.55%)
Regular-session close
104.74 +0.03 +0.03%
Pre-market · Nov 18, 8:47 AM ET
104.59 Day range 108.18
81.97 52-week range 131.49
- YTD
- -16.43%
- 1 year
- -19.47%
Benzinga news
benzinga.com Ken Griffin Dumps SpaceX, Amazon; Buys ARKK and Bets Big on Marvell Inside Citadel's Q3 13F: Ken Griffin slashed AMD and Amazon, raised Marvell 729%, and quietly unwound Leopold Aschenbrenner's AI fund.
benzinga.com Abbott Touts Favorable Outcomes In Cardiovascular Device Trials Abbott reports positive trial results for its Amulet 360 LAA occluder and SonicForce coronary IVL system at a conference.benzinga.com Abbott Announces One-Year Results For Its Amulet 360 Left Atrial Appendage Occluder From The VERITAS Study; Data Show Meaningful Closure Rates Of Left Atrial Appendage And A Low Incidence Of Stroke In People With Atrial Fibrillation Not Caused By A Heart Valve Issue The data were presented in a late-breaking session at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego, Calif., on Nov. 1, 2026, and simultaneously published in JACC:…
benzinga.com Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary…
benzinga.com Abbott Initiates CROWN-MV Pivotal Trial Evaluating Safety And Effectiveness Of Its Investigational Cephea Mitral Valve System For Symptomatic Mitral Valve Disease CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people with symptomatic mitral valve disease who are not candidates for…
benzinga.com This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.benzinga.com Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular…
benzinga.com Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120 Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.
benzinga.com Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect®…
benzinga.com Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122 Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.
benzinga.com RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125 RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.
benzinga.com Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119 Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $112 to $119.
benzinga.com JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118 JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.
benzinga.com TD Cowen Maintains Buy on Abbott Laboratories, Lowers Price Target to $118 TD Cowen analyst Joshua Jennings maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $118.
benzinga.com Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123 Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.
benzinga.com BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $125 BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.
benzinga.com SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
benzinga.com Abbott CEO Rules Out Selling $8.5 Billion Nutrition Business: 'No Interest' Abbott (ABT) to spin off its $8.5B nutrition arm, makers of Ensure & Similac, by end of 2027. Stock dips following Q3 results.
benzinga.com Meta, Tesla On Deck Wednesday As AI Spending, Auto Demand Face Test Meta Platforms and Tesla headline Wednesday’s reports, with investors focused on whether AI investment can keep driving growth while Tesla’s core auto business weakens. Philip Morris International,…
benzinga.com Abbott Laboratories Q3 2026 Earnings Call Transcript Abbott Laboratories (NYSE:ABT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Abbott Laboratories Narrows FY2026 Adj EPS Guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 Est Abbott Laboratories (NYSE:ABT) narrows FY2026 Adj EPS guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 analyst estimate..
benzinga.com Abbott Laboratories Q3 Adj. EPS $1.42, Inline, Sales $13.013B Beat $12.998B Estimate Abbott Laboratories (NYSE:ABT) reported quarterly earnings of $1.42 per share which met the analyst consensus estimate. This is a 9.23 percent increase over earnings of $1.30 per share from the same…
benzinga.com Abbott To Spin Off Nutrition Business Into Independent Public Company With $8.5B In Annual Sales; Separation Expected To Be Completed By 2027 End Separation will unlock potential of both companies to pursue distinct growth and value-creation strategiesThe new Nutrition company will be a global leader in the rapidly growing healthy nutrition…
benzinga.com How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings Abbott expects Q3 EPS of $1.41 and $12.99B revenue. Its 2.42% dividend requires about $247,767 invested to generate $500 monthly.
benzinga.com Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings Abbott reports Q3 earnings Oct. 21; analysts expect $1.41 EPS and $12.99B revenue. FDA approved CardioMEMS updates.
